A

Amgen

Makes biotech medicines for serious illnesses

Senior Machine Learning Engineer

Full-TimeUpdated on 10/13/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Applied Machine Learning, AI & Machine Learning

About the job

Requirements
  • A Bachelor's or Master's degree in Computer Science, IT, or a related field, with 8–13 years of experience.
  • Advanced software and AI/ML system design, including production Python and SQL, APIs, distributed or event-driven services, data persistence, testing, performance, repository governance, design review, and end-to-end architecture.
  • Advanced statistics, machine learning, and experimental design, including exploratory data analysis, feature engineering, supervised and unsupervised learning, predictive modeling, ensembles, anomaly detection, calibration, uncertainty, robustness, explainability, and causal reasoning where justified.
  • Deep learning, natural language processing, and foundation models, including production use of neural, transformer, embedding, vision, document, and multimodal approaches, and trade-offs involving fine-tuning versus prompting, latency, privacy, and cost.
  • Generative AI, retrieval-augmented generation, knowledge systems, and agentic AI, including grounded retrieval, structured output, provenance, citations, abstention, entitlement controls, bounded tool use, permissions, durable state, recovery, adversarial evaluation, and human control.
  • Data, knowledge, cloud, and AI operations, including trustworthy batch and streaming pipelines, data contracts, lineage, vector and graph stores, Spark or Databricks, containers, Kubernetes, machine-learning and large-language-model operations, service-level objectives, and lifecycle operations.
  • Responsible AI and regulated delivery, including risk assessment, least privilege, threat modeling, red teaming, bias and subgroup robustness, privacy, model and data documentation, human accountability, validation, and applicable GxP controls.
  • Demonstrated end-to-end ownership of at least one production machine-learning, generative-AI, software, data, or automation system that delivered a measurable outcome.
  • Strong hands-on proficiency in Python and SQL, including experience designing production software, services, and evaluation pipelines.
  • Advanced capability in at least one role-defining pillar—applied machine learning, generative AI/retrieval-augmented generation/agents, or machine-learning platform/operations—plus credible depth across the production lifecycle.
  • Strong product thinking and ability to connect technical decisions to users, workflows, risk, cost, and business value.
  • Technical leadership, mentoring, and constructive challenge while remaining hands-on.
  • Analytical judgment and clear communication of evidence, uncertainty, trade-offs, and limitations.
  • Cross-functional leadership across business, product, architecture, engineering, and control functions.
  • Ownership, resilience, and continuous improvement through incidents, feedback, and measured outcomes.
Responsibilities
  • Define the user, workflow, decision, intended use, baseline, value hypothesis, acceptance criteria, adoption path, operating owner, and measurable technical and business outcomes.
  • Map rules, exceptions, data dependencies, and human decision points before selecting deterministic automation, classical machine learning, deep learning, generative AI, retrieval-augmented generation, agents, or a manual approach.
  • Own production architecture across data, feature and knowledge pipelines, models, retrieval, agents, APIs, persistence, workflows, user experience, security zones, and human review.
  • Lead hands-on development of production software, exploratory data analysis, feature engineering, predictive models, deep-learning or natural-language-processing components, inference services, retrieval-augmented generation, agent tools, and workflow orchestration.
  • Establish baselines, experiment design, leakage controls, uncertainty, calibration, subgroup and robustness checks, gold sets, error taxonomies, expert adjudication, and release thresholds.
  • Establish machine-learning and large-language-model operations for lineage, reproducibility, versioning, continuous integration and deployment, canary or shadow release, observability, drift monitoring, service-level objectives, rollback, incidents, disaster recovery, capacity, cost, and runbooks.
  • Coordinate security, privacy, Responsible AI, Quality, legal, model-risk, and GxP controls; create reusable capabilities, measure adoption and value, mentor engineers, and improve delivery practices.
Desired Qualifications
  • Experience with data-centric AI, weak supervision, active learning, conformal or Bayesian uncertainty, causal inference, time-series, survival methods, or drift-aware retraining.
  • Experience with transformers, multimodal pipelines, convolutional neural networks, recurrent neural networks, graph neural networks, parameter-efficient fine-tuning or LoRA, fine-tuning, distillation, quantization, routing, cascades, or inference optimization.
  • Experience with AWS, Bedrock or SageMaker, Databricks, Spark, Kubernetes, serverless systems, infrastructure as code, MLflow, Airflow, Kubeflow, observability, or FinOps.
  • Experience with review, correction, approval, accessibility, uncertainty communication, workflow automation, and GxP-relevant or validated systems.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.